GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -0.50 (-3.23%)
Spread: 0.50 (3.333%)
Open: 15.00
High: 15.50
Low: 14.65
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

15 Feb 2010 17:41

RNS Number : 1825H
Angle PLC
15 February 2010
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

ANGLE plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

RBC Holdings (Channel Islands) Limited

4. Full name of shareholder(s)

(if different from 3.):iv

Roy Nominees

5. Date of the transaction and date on which the threshold is crossed or reached: v

4 Feb 2010

6. Date on which issuer notified:

15 Feb 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0034330679

790,000

790,000

832,120

832,120

3.07

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

832,120

3.07

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Roy Nominees is a nominee company for RBC Trustees (CI) Limited and RBC cees Trustee Limited which are wholly owned subsidiaries of RBC Holdings (Channel Islands) Limited. The ultimate parent of the latter is Royal Bank of Canada.

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Ian Griffiths

15. Contact telephone number:

+44 (0)1483 685 830

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLTAMRTMBJBBLM
Date   Source Headline
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.